Physician profile
Shereen Hashmi
NPI 1033159322
$25,030.16
in general payments reported to CMS, 2019-2025
40 companies · $3,480 in 2025
The $3,480 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,340 · 2020: $3,191 · 2021: $3,538 · 2022: $3,555 · 2023: $3,527 · 2024: $3,398 · 2025: $3,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,932 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,931.82 |
| Education | $474.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,190.95 | 2019-2025 | |
| Amgen INC. | $3,981.11 | 2019-2025 | Enbrel, Otezla, Otezla |
| Janssen Biotech, INC. | $3,428.80 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,593.29 | 2019-2025 | |
| Ucb, INC. | $1,155.28 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $1,008.60 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $988.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $985.41 | 2019-2025 | Orencia |
| Lilly USA, LLC | $891.52 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $834.54 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $595.21 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Radius Health, INC. | $518.50 | 2020-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $397.47 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $234.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $233.97 | 2022-2025 | Soliris, Strensiq, Ultomiris |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereen Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.